Methods of vaccine administration
This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.
1. A method of eliciting protective titer against Canine Distemper (CD) virus in a serum of a dog comprising administering to the dog therapeutically effective amounts of vaccine, wherein the vaccine comprises modified live or attenuated Canine Distemper (CD) Virus, wherein the vaccine is administered orally in a first dose, orally in a second dose, and orally in one or more annual doses, wherein said protecting titer against CD is greater than or equal to 1:32 at three weeks after said second vaccination.
2. The method of claim 1 wherein said vaccine further comprises one or more of Canine Adenovirus-2 (Cav-2), and Canine Parvovirus (CPV).
3. The method of claim 2 , wherein said Adenovirus-2 (Cav-2), and Canine Parvovirus (CPV) are attenuated or modified live viruses.
4. The method of claim 3 , wherein said vaccine further comprises Canine Parainfluenza Virus (CPI).
5. The method of claim 3 , wherein said vaccine is not adjuvanted.
6. The method according to claim 3 , wherein the vaccine further comprises a bacterin selected from the group consisting of Bordetella bronchiseptica, Leptospira canicola, L. grippotyphosa, L. icterohaemorrhagiae , and L. pomona.
7. The method according to claim 1 , wherein the vaccine further comprises a bacterin selected from the group consisting of Bordetella bronchiseptica, Leptospira canicola, L. grippotyphosa, L. icterohaemorrhagiae , and L. pomona.
8. The method of claim 1 , wherein said vaccine is not adjuvanted.
9. The method according to claim 1 , wherein the viral antigens are CD virus, CAV-2, CPI virus, and CPV, and the bacterium in the bacterin is Bordetalla bronchiseptica.
10. The method according to claim 1 , wherein said vaccine is not adjuvanted.
11. The method according to claim 1 , wherein the CD antigen is in the range of between present in the following ranges of amounts: for CD virus, about 10 2 TCID 50 to about 10 8 TCID 50 , inclusive.
12. A method according to claim 1 , wherein the second dose is administered from 7 to 35 days, inclusive, after the first dose.
13. A method according to claim 1 , further comprising orally administering a third dose of said vaccine, wherein the third dose is administered from 7 to 35 days, inclusive, after the second dose.
14. A method according to claim 1 , wherein a first annual dose is administered about one year after the first dose.